IST5-002 inhibited STAT5 phosphorylation and reduced the growth and viability of several chronic myeloid leukaemia (CML) cell lines, including those resistant to current therapies. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.